Jaguar health completes final regulatory filing for conditional new animal drug approval of canalevia (crofelemer) to treat exercise-induced diarrhea (eid) in dogs

Canalevia® would be the first and only treatment for eid in dogs to receive any type of approval from fda san francisco, ca / accesswire / may 3, 2022 / jaguar health, inc. (nasdaq:jagx), under its jaguar animal health tradename for the veterinary market, today announced that it has completed filing of the final regulatory section with the u.s. food and drug administration's (fda) center for veterinary medicine (cvm) to support conditional new animal drug approval of the company's oral plant-based drug candidate canalevia (crofelemer delayed-release tablets) to treat exercise-induced diarrhea (eid) in dogs. in december of 2021, jaguar animal health received conditional approval from the fda for canalevia®-ca1 for chemotherapy-induced diarrhea (cid) in dogs.
JAGX Ratings Summary
JAGX Quant Ranking